Roche
Founded Year
1896Stage
PIPE - II | IPOMarket Cap
207.54BStock Price
264.00Revenue
$0000About Roche
Roche operates as a company in pharmaceuticals and diagnostics, with a focus on science related to health outcomes. The company offers medicines and diagnostic tools aimed at preventing, diagnosing, and treating diseases across various medical fields. Roche ensures that treatments are tailored to meet the individual needs of patients. It was founded in 1896 and is based in Basel, Switzerland.
Loading...
ESPs containing Roche
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…
Roche named as Leader among 15 other companies, including Becton Dickinson, Exact Sciences, and Caris Life Sciences.
Loading...
Research containing Roche
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Roche in 6 CB Insights research briefs, most recently on Sep 8, 2025.
Expert Collections containing Roche
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Roche is included in 1 Expert Collection, including Conference Exhibitors.
Conference Exhibitors
5,302 items
Roche Patents
Roche has filed 954 patents.
The 3 most popular patent topics include:
- molecular biology
- biotechnology
- analytical chemistry
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/25/2020 | 4/8/2025 | Mass spectrometry, Ion source, Molecular biology, Molecular biology techniques, Nanotechnology | Grant |
Application Date | 8/25/2020 |
|---|---|
Grant Date | 4/8/2025 |
Title | |
Related Topics | Mass spectrometry, Ion source, Molecular biology, Molecular biology techniques, Nanotechnology |
Status | Grant |
Latest Roche News
Nov 5, 2025
20.55亿美元！罗氏加码透脑递送技术，突破CNS瓶颈 请感兴趣的公司立即联系 来源： Manifold Bio官网 罗氏将向Manifold支付5500万美元的预付款，后者还有资格获得总计超过20亿美元的重要研究、发现和临床前里程碑以及临床和销售里程碑，以及分级特许权使用费。此外，Manifold保留共同资助某一项目开发的权利，以换取更高的版税比例，并可将其BBB穿梭技术应用于罗氏许可靶点以外的其他治疗载荷。 挑一辆“好车”进入血脑屏障 血脑屏障作为大脑天然的保护屏障，由紧密连接的脑毛细血管内皮细胞构成，能有效阻挡血液中的毒素和病原体。然而，这一生理防线也严重限制了绝大多数治疗性分子，尤其是大分子生物制剂（如抗体、酶、基因疗法载体）进入中枢神经系统，成为CNS疾病，如阿尔茨海默症、帕金森病药物研发长期面临的“卡脖子”难题。 过去二十余年，科学界逐渐摒弃“强行穿透”的思路，转而探索“智取”策略：即利用大脑内皮细胞上天然存在的受体介导转运（RMT）通路，设计分子“穿梭机”，将治疗性大分子药物以“搭便车”形式递送入脑。这一策略的核心在于精准识别并工程化改造能高效穿越 BBB 的载体分子。 Manifold Bio的技术平台正是这一范式的前沿代表。其核心引擎 mDesign 脱胎于哈佛大学George Church博士实验室，融合了AI引导的蛋白质设计与高通量体内筛选能力。不同于传统依赖体外模型的研发路径，mDesign平台通过DNA条形码技术对数千至数百万种生物变体进行标记，可在活体内直接完成大规模筛选与功能验证，从而获取具有生理相关性的药物递送数据。 基于该平台，Manifold已系统性地测量并优化了数千种潜在BBB穿梭器，这些穿梭器可靶向多个内源性受体通路，并能与抗体融合或与siRNA、ASO等多种治疗模态偶联，显著提升药物在脑内的富集效率与治疗窗口，从而扩大可创建的候选产品的广度、有效性和安全性。 该公司正在利用其平台寻求组织靶向药物的广泛机会，包括使用基于抗体的血脑屏障穿梭机将药物输送到大脑，这是合作的重点。 挑”好车“后，造CNS”好药” 罗氏在CNS领域深耕多年，尤其在BBB穿梭技术方面已有深厚积累。其基于该技术开发的双特异性抗体trontinemab（靶向 β-淀粉样蛋白与转铁蛋白受体）在 2025 年 7 月阿尔茨海默病协会国际会议（AAIC）上公布的 Ib/IIa 期数据显示：其中91%的受试者在淀粉样蛋白正电子发射断层扫描（PET）评估中转为阴性，且与水肿/渗出相关的淀粉样蛋白成像异常（ARIA-E）发生率保持在5%以下，展现出快速且强效的斑块清除能力，验证了BBB穿梭策略的临床可行性。 图注：trontinemab机制图 来源：罗氏官方公布 BBB技术合作如火如荼 2025年7月8日，阿斯利康旗下罕见病业务部门 Alexion与日本JCR 制药公司宣布达成一项非独占许可协议，获得后者专有的 JUST-AAV衣壳平台 的开发权。这项协议的预付款及总计高达8.25亿美元，并且这已经是双方的第三次合作。 此前，Alexion 已利用 JCR的血脑屏障穿透技术J-Brain Cargo® 技术，开发针对神经退行性疾病的创新疗法以及将该技术用于开发寡核苷酸疗法。此次合作的 JUST-AAV 平台则是在原有基础上的重大升级：通过在腺相关病毒（AAV）衣壳中嵌入小型抗 TfR 抗体片段，实现对BBB上TfR 的高效靶向，从而显著提升基因治疗载体穿越血脑屏障的能力。 值得一提的是，JCR 制药是全球首家成功将“穿梭机技术“转化为获批药物的企业。 紧随其后的一天，中国创新生物技术公司维泰瑞隆（Sironax） 宣布与诺华达成战略合作。根据协议，诺华获得一项独家选择权，可在评估期内收购Sironax自主研发的「脑部递送模组」（BDM）平台。该平台是一种差异化的血脑屏障穿透技术，旨在提高多种形式药物的脑部递送效率，交易潜在价值达1.75 亿美元。此举不仅体现了国际巨头对中国原创递送技术的认可，也标志着本土企业在CNS 递送这一高壁垒领域实现突破。 仅一个月后，诺华再次加码 BBB 递送赛道。2025年8月26日，BioArctic AB宣布与诺华达成合作，共同开发基于其专有的脑部递送（BrainTransporter）技术与未公开的CNS靶点结合，开发新疗法，交易潜在价值达8.02亿美元！ 结语 参考资料：
Roche Frequently Asked Questions (FAQ)
When was Roche founded?
Roche was founded in 1896.
Where is Roche's headquarters?
Roche's headquarters is located at Grenzacherstrasse 124, Basel.
What is Roche's latest funding round?
Roche's latest funding round is PIPE - II.
Who are the investors of Roche?
Investors of Roche include SoftBank, Scale AI and BioMedPartners.
Who are Roche's competitors?
Competitors of Roche include MorphoSys, PreludeDX, Viatris, AbbVie, Genentech and 7 more.
Loading...
Compare Roche to Competitors
Novartis develops and offers a range of medicines aimed at treating serious diseases, providing support for patients and healthcare professionals, and conducting research to discover new therapies. The company also focuses on environmental sustainability and ethical practices in the pharmaceutical industry. It was founded in 1996 and is based in Basel, Switzerland.
Boehringer Ingelheim operates within the pharmaceutical and animal health sectors. The company conducts research and development of products for humans and animals. Boehringer Ingelheim serves the healthcare industry with an emphasis on pharmaceutical products. It was founded in 1885 and is based in Ingelheim am Rhein, Germany.
Teva México specializes in the pharmaceutical industry, focusing on the development and manufacturing of generic medications. The company offers a range of generic medicines designed to improve health outcomes for patients. Teva México primarily serves the healthcare sector by providing medication options. It is based in Ciudad de México, Mexico.
Pfizer is a biopharmaceutical company involved in the discovery, development, and manufacturing of medications and vaccines aimed at improving health outcomes. The company serves the healthcare sector with its medical solutions. It is based in Jakarta, Indonesia.
Sumitomo Pharma is a biopharmaceutical company focused on developing therapeutic and scientific breakthroughs. The company's main offerings include the development of novel cancer therapeutics and a robust pipeline of treatments aimed at addressing unmet clinical needs in oncology. Sumitomo Pharma was formerly known as Sumitomo Dainippon Pharma. It was founded in 1897 and is based in Osaka, Japan.
Taisho Pharmaceutical operates in the pharmaceutical industry. It provides medicinal drugs and over-the-counter medications. It was founded in 1912 and is based in Tokyo, Japan. In January 2024, Taisho Pharmaceutical was acquired by Otemon at a valuation of $4.88B.
Loading...